Solid Biosciences reports that 33 children have now been dosed in their SGT-003 gene therapy trial for Duchenne. So far, the treatment has been generally well tolerated with signs of improved muscle and heart biomarkers. Their global Phase 3 trial is also underway, with the first participant enrolled.
Press Release: https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-provides-2026-outlook-underscoring
Community Letter: https://www.solidbio.com/letter-to-the-duchenne-community-2/
The post Solid Biosciences Reports Progress on Next-Generation Gene Therapy appeared first on CureDuchenne.